Trials / Completed
CompletedNCT02106260
First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts
A Phase I/IIa Open-label First-in-Human Study to Assess Safety and Pharmacokinetics and Explore Biomarker Effects of Topical Ionic Contra-viral Therapy (ICVT) Comprised of CLS003 in Subjects With Cutaneous Warts
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Maruho Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This phase I/IIa study has an open-label, First-in-Human (FIH), single center design to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of topically applied CLS003 in healthy subjects with cutaneous warts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CLS003 |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2014-04-01
- First posted
- 2014-04-08
- Last updated
- 2014-05-23
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02106260. Inclusion in this directory is not an endorsement.